Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Peters, S Dafni, U Boyer, M De, R Felip, E Garrido, P Girard, N Guckenberger, M Haanen, J
Peters, S
Dafni, U
Boyer, M
De, R
Felip, E
Garrido, P
Girard, N
Guckenberger, M
Haanen, J
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 Jan 8.